Thalidomide
Adrenoleukodystrophy
FDA Office of Orphan Products DevelopmentSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Adrenoleukodystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Ctc-501 Massachusetts General Hospital | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Clofarabine Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 19 →
Same molecule, other indications
Thalidomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →